'Another Good Year' Ahead for AstraZeneca: CEO Pascal Soriot

The transcript covers the financial outlook for 2023, highlighting expected growth despite economic challenges. It discusses the potential impact of a new lung cancer drug and the success of a breast cancer treatment. The challenges and opportunities in the Chinese pharmaceutical market are explored, along with a comparison of R&D environments in Europe and the US. Finally, the CEO discusses succession planning and the company's strategic direction.

What challenges has the pharmaceutical industry faced in China due to COVID?

What does the speaker believe is necessary for creating a successful life sciences sector?

What are the key components of the succession plan mentioned by the speaker?